Security key
29664W105
- Security type / class
- Equity / COM
- Total 13F shares
- 17,848,619
- Total 13F value
- $56,305,549
- Share change
- +1,277,461
- Put/Call ratio
- 236%
- SEC-reported price per share
- $3.16
- Number of holders
- 34
- Value change
- +$4,122,975
- Number of buys
- 12
- Number of sells
- 18
- Shares outstanding
- 275,740,714
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2026
Institutions
34
Top holders
10
ESPR full security history
Ownership snapshot
Full 13F holder table
Previous quarter: Q1 2026
Esperion Therapeutics, Inc. SEC filings
Esperion Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 29664W105
Recent filing periods:
Ownership snapshot
Top reported holders of ESPR - Esperion Therapeutics, Inc. - COM (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
GLAZER CAPITAL, LLC
Disclosed value leader
GLAZER CAPITAL, LLC
Comparable rows
15/15
Latest evidence
01 Jun 2026
13D/G
13F
Lead comparable stake: 8.2%
13D/G row: GLAZER CAPITAL, LLC
Showing 1-6 of 15 holder rows.
Quick read
GLAZER CAPITAL, LLC leads the comparable SEC ownership view at 8.2%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens GLAZER CAPITAL, LLC's linked filing trail.
Comparable ownership
Top 5
GLAZER CAPITAL, LLC
8.2%
BB BIOTECH AG
4.9%
Two Seas Capital LP
4.7%
WASATCH ADVISORS LP
0.7%
BlackRock, Inc.
6.5%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| GLAZER CAPITAL, LLC |
13D/G
|
8.2%
|
$65,443,934
20,975,620 shares
|
$0 | 01 Jun 2026 |
| BB BIOTECH AG |
13D/G
|
4.9%
|
$8,821,598
9,694,064 shares
|
-$227,500 | 04 Mar 2025 |
| Two Seas Capital LP |
13F
13D/G
Company
|
4.7%
from 13D/G
|
$31,221,842
11,394,833 shares
|
— | 31 Mar 2026 |
| WASATCH ADVISORS LP |
13F
13D/G
Company
|
0.7%
from 13D/G
|
$43,206,778
15,768,897 shares
|
— | 31 Mar 2026 |
| BlackRock, Inc. |
13F
Company
|
6.5%
|
$48,915,650
17,852,427 shares
|
— | 31 Mar 2026 |
| ORBIMED ADVISORS LLC |
13F
Company
|
3.8%
|
$28,962,622
10,570,300 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
34
Shares
17,848,619
Rows available
34
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2026 vs Q1 2026 Across Filers
Q1 2026 holders
204
Q2 2026 holders
34
Holder diff
-170
| Investor | Q1 2026 Shares | Q2 2026 Shares | Share Diff | Share Chg % | Q1 2026 value | Q2 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend